Five Prime Therapeutics (FPRX) Misses Q2 EPS by 37c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21).

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance